Several drugs commonly used to treat COVID-19 patients were tested for their potential to restore cytokine balance in vitro, notably to increase IFNγ production and decrease the production of inflammatory cytokines, while keeping the secretion of regulatory cytokines constant. This evidence concerns the gene IFNG and COVID-19.